Items where authors include "Boehncke, W-H"

Article

Zabotti, A, De Marco, G orcid.org/0000-0003-2406-161X, Gossec, L et al. (26 more authors) (2023) EULAR points to consider for the definition of clinical and imaging features suspicious for progression from psoriasis to psoriatic arthritis. Annals of the Rheumatic Diseases. ISSN 0003-4967

Nash, P, Kerschbaumer, A, Dörner, T et al. (26 more authors) (2021) Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement. Annals of the Rheumatic Diseases, 80 (1). pp. 71-87. ISSN 0003-4967

Mease, PJ, Gladman, DD, Deodhar, A et al. (9 more authors) (2020) Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study. RMD Open, 6 (2). e001217. ISSN 2056-5933

Deodhar, A, Helliwell, PS, Boehncke, W-H et al. (9 more authors) (2020) Guselkumab in patients with active psoriatic arthritis who were biologic-naive or had previously received TNFα inhibitor treatment (DISCOVER-1): a double-blind, randomised, placebo-controlled phase 3 trial. The Lancet, 395 (10230). pp. 1115-1125. ISSN 0140-6736

Coates, LC orcid.org/0000-0002-4756-663X, FitzGerald, O, Merola, JF et al. (23 more authors) (2018) Group for Research and Assessment of Psoriasis and Psoriatic Arthritis/Outcome Measures in Rheumatology Consensus-Based Recommendations and Research Agenda for Use of Composite Measures and Treatment Targets in Psoriatic Arthritis. Arthritis & Rheumatology, 70 (3). pp. 345-355. ISSN 2326-5191

Mease, PJ, Helliwell, PS, Boehncke, W-H et al. (5 more authors) (2016) GRAPPA 2015 Research and Education Project Reports. The Journal of Rheumatology, 43 (5). pp. 979-985. ISSN 0315-162X

Gladman, DD, Mease, PJ, Boehncke, W-H et al. (2 more authors) (2016) Presidential Round Table: A Report from the GRAPPA Annual Meeting. The Journal of Rheumatology, 43 (5). pp. 986-989. ISSN 0315-162X

Boehncke, W-H, Gladman, DD and Helliwell, PS (2016) Prologue: 2015 Annual Meeting of the Group for Research and Assessment of Psoriasis and Psoriatic Arthritis (GRAPPA). The Journal of Rheumatology, 43 (5). pp. 949-951. ISSN 0315-162X

Conference or Workshop Item

Rahman, P, Ritchlin, C, Mease, P et al. (10 more authors) (2022) Long-term Safety of Guselkumab in Patients With Active Psoriatic Arthritis: Pooled Results From 3 Randomized Clinical Trials Through Up to 2 Years. In: Open Access Canadian Rheumatology Association Annual Meeting, 02-05 Feb 2022, Online.

Rahman, P, Ritchlin, C, Mease, P et al. (11 more authors) (2021) Long-term Safety of Guselkumab (TREMFYA (R)) in Patients with Active Psoriatic Arthritis: Pooled Results from 3 Randomized Clinical Trials Through up to 2 Years. In: ACR Convergence 2021, 05-09 Nov 2021, Online.

Mease, P, Foley, P, Reich, K et al. (14 more authors) (2021) Low Incidence of Gastrointestinal-related and Overall Serious Adverse Events Among Guselkumab-treated Patients: Pooled Analyses of VOYAGE 1 & 2 and DISCOVER 1 & 2 Through 1-Year. In: ACR Convergence 2021, 05-09 Nov 2021, Online.

Ritchlin, CT, Rahman, P, Helliwell, PS orcid.org/0000-0002-4155-9105 et al. (7 more authors) (2021) Safety of guselkumab in patients with psoriatic arthritis through 1 year: Pooled findings from DISCOVER-1 and DISCOVER-2 phase 3 trials. In: AAD VMX 2021, 23-25 Apr 2021, Virtual.

Ritchlin, C, Deodhar, A, Boehncke, W-H et al. (10 more authors) (2020) Guselkumab Efficacy and Safety in TNF-Inhibitor-Experienced and TNF-Inhibitor-Naive Patients with Active PsA: 1-Year Results of a Phase 3, Randomized, Controlled Study. In: ACR Convergence 2020, 05-09 Nov 2020, Virtual.

Ritchlin, C, Helliwell, P orcid.org/0000-0002-4155-9105, Boehncke, W-H et al. (8 more authors) (2020) Guselkumab, an IL-23 Inhibitor That Specifically Binds to the IL23p19-Subunit, for Active Psoriatic Arthritis: One Year Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Patients Who Were Biologic-Naïve or TNFα Inhibitor-Experienced. In: ACR Convergence 2020, 05-09 Nov 2020, Virtual.

Deodhar, A, Helliwell, P, Boehncke, W-H et al. (8 more authors) (2020) P262 Guselkumab, an anti-interleukin-23p19 monoclonal antibody, in patients with active PsA who were biologic-naïve or prior TNFα inhibitor-treated: week 24 results of a Phase 3, randomised, double-blind, placebo-controlled study. In: British Society for Rheumatology Annual Conference, 20-22 Apr 2020, Online.

Deodhar, A, Kirkham, B, Rahman, P et al. (6 more authors) (2020) P277 Assessment of disease activity using RAPID3 and evaluation of treatment effect of guselkumab in patients with PsA: results from a randomised placebo-controlled Phase 2 clinical trial. In: British Society for Rheumatology Annual Conference 2020, 20-22 Apr 2020, Cancelled.

Gladman, D, Boehncke, W-H, Gottlieb, AB et al. (7 more authors) (2019) The Effect of Guselkumab on Dactylitis: Results from a Phase 2 Study in Patients with Active Psoriatic Arthritis. In: Pan-American Congress of Rheumatology 2019, 27-30 Apr 2019, Quito, Ecuador.

Helliwell, P, Gottlieb, AB, Deodhar, A et al. (7 more authors) (2019) The Effect of Guselkumab on Enthesitis: Results from a Phase 2 Study in Patients with Active Psoriatic Arthritis. In: Pan-American Congress of Rheumatology 2019, 27-30 Apr 2019, Quito, Ecuador.

Proceedings Paper

Helliwell, P, Deodhar, A, Gottlieb, AB et al. (7 more authors) (2019) Comparing Composite Measures of Disease Activity in Psoriatic Arthritis: Results From a Randomized Phase 2 Trial with Guselkumab. In: Annals of the Rheumatic Diseases. EULAR 2019: Annual European Congress of Rheumatology, 12-15 Jun 2019, Madrid, Spain. BMJ Publishing Group , p. 1843.

Gossec, L, Kirkham, B, Rahman, P et al. (4 more authors) (2018) Clinically Meaningful Improvement in Health-Related Quality of Life and the Association with Disease Activity in Psoriatic Arthritis after Treatment with Guselkumab: Results from a Randomized Placebo-Controlled Phase II Clinical Trial. In: Arthritis and Rheumatology. 2018 ACR/ARHP Annual Meeting, 19-24 Oct 2018, Chicago, IL, USA. Wiley .

Gladman, DD, Boehncke, W-H, Gottlieb, AB et al. (8 more authors) (2018) The Effect of Guselkumab on Dactylitis: Results from a Phase 2 Study in Patients with Active Psoriatic Arthritis. In: Arthritis and Rheumatology. 2018 ACR/ARHP Annual Meeting, 19-24 Oct 2018, Chicago, IL, USA. Wiley .

Helliwell, P, Gottlieb, AB, Deodhar, AA et al. (8 more authors) (2018) The Effect of Guselkumab on Enthesitis: Results from a Phase 2 Study in Patients with Active Psoriatic Arthritis. In: Arthritis and Rheumatology. 2018 ACR/ARHP Annual Meeting, 19-24 Oct 2018, Chicago, IL, USA. Wiley .